Gene-Modified Lymphocytes, High-Dose Aldesleukin, and Vaccine Therapy in Treating Patients With Progressive or Recurrent Metastatic Cancer

Inclusion Criteria

• •DISEASE CHARACTERISTICS:
• •Diagnosis of metastatic cancer
• •Tumor overexpresses p53 as assessed by immunohistochemistry (i.e., ≥ 5% tumor cells stain positive for p53)
• •* Biopsy must be available to evaluate p53 expression
• •Human leukocyte antigens 0201 (HLA-A\*0201) positive
• •Progressive or recurrent disease after prior standard therapy for metastatic disease
• •* Patients with melanoma or renal cell cancer must have previously received aldesleukin
• •* Patients with other histologies, not including hematologic malignancies, must have previously received first-line and second-line or higher systemic standard therapy (or effective salvage chemotherapy regimens)
• •PATIENT CHARACTERISTICS:
• •Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
• •Life expectancy \> 3 months
• •Absolute neutrophil count \> 1,000/mm\^3
• •White blood cell (WBC) \> 3,000/mm\^3
• •Platelet count \> 100,000/mm\^3
• •Hemoglobin \> 8.0 g/dL
• •Serum alanine aminotransferase (ALT)/aspartate aminotransferase (AST) ≤ 2.5 times upper limit of normal
• •Serum creatinine ≤ 1.6 mg/dL
• •Total bilirubin ≤ 2.0 mg/dL (\< 3.0 mg/dL in patients with Gilbert's syndrome)
• •Not pregnant or nursing
• •Negative pregnancy test
• •Fertile patients must use effective contraception during and for 4 months after completion of study treatment
• •Patients who have previously received ipilimumab or ticilimumab must have a normal colonoscopy with normal colonic biopsies
• •Human immunodeficiency virus (HIV) antibody negative
• •Hepatitis B antigen and hepatitis C antibody negative (unless antigen negative)
• •No primary immunodeficiency (e.g., severe combined immunodeficiency disease)
• •No active systemic infections
• •No history of severe immediate hypersensitivity reaction to any of the agents used in this study
• •No coagulation disorders
• •No myocardial infarction or cardiac arrhythmias
• •No history of coronary revascularization
• •No obstructive or restrictive pulmonary disease
• •No contraindications for high-dose aldesleukin administration
• •Left ventricular ejection fraction (LVEF) ≥ 45% in patients meeting any of the following criteria:
• •* History of ischemic heart disease,
• •* chest pain,
• •* or clinically significant atrial and/or ventricular arrhythmias including, but not limited to, atrial fibrillation,
• •* ventricular tachycardia,
• •* or second- or third-degree heart block
• •* At least 60 years of age
• •Forced expiratory volume 1 (FEV\_1) \> 60% predicted in patients meeting any of the following criteria:
• •* Prolonged history of cigarette smoking (\> 20 pack/year within the past 2 years)
• •* Symptoms of respiratory dysfunction
• •No other major medical illness of the cardiovascular,
• •* respiratory,
• •* or immune system
• •PRIOR CONCURRENT THERAPY:
• •See Disease Characteristics
• •Recovered from prior therapy
• •More than 4 weeks since prior and no concurrent systemic steroid therapy
• •More than 4 weeks since other prior systemic therapy
• •More than 6 weeks since prior ipilimumab